Economic burden of haematological adverse effects in cancer patients: a systematic review.
about
Optimal first-line chemotherapeutic treatment in patients with locally advanced or metastatic esophagogastric carcinoma: triplet versus doublet chemotherapy: a systematic literature review and meta-analysisNilotinib versus dasatinib as second-line therapy in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase who are resistant or intolerant to imatinib: a cost-effectiveness analysis based on real-world data.Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib.Incidence and risk factors of clinically significant chemotherapy-induced thrombocytopenia in patients with solid tumors.Analysis of the risk factors for myelosuppression after concurrent chemoradiotherapy for patients with advanced non-small cell lung cancer.Effects of Designer Hyper-Interleukin 11 (H11) on Hematopoiesis in Myelosuppressed MiceTranscutaneous electrical acupoint stimulation (TEAS) ameliorates chemotherapy-induced bone marrow suppression in lung cancer patients.Outpatient management of cancer patients with febrile neutropenia: a systematic review and meta-analysis.Costs associated with febrile neutropenia in solid tumor and lymphoma patients - an observational study in SingaporeCost effectiveness of outpatient treatment for febrile neutropaenia in adult cancer patients.Cost-effectiveness analysis of everolimus plus exemestane versus exemestane alone for treatment of hormone receptor positive metastatic breast cancer.Impact of febrile neutropenia on R-CHOP chemotherapy delivery and hospitalizations among patients with diffuse large B-cell lymphomaCost effectiveness of integrated medicine in patients with cancer receiving anticancer chemotherapy.Andrographis paniculata elicits anti-invasion activities by suppressing TM4SF3 gene expression and by anoikis-sensitization in esophageal cancer cellsCOST OF FEBRILE NEUTROPENIA TREATMENT IN BOSNIA AND HERZEGOVINA.Am80-GCSF synergizes myeloid expansion and differentiation to generate functional neutrophils that reduce neutropenia-associated infection and mortality.Neutropenia management and granulocyte colony-stimulating factor use in patients with solid tumours receiving myelotoxic chemotherapy--findings from clinical practicePatterns of chemotherapy-associated toxicity and supportive care in US oncology practice: a nationwide prospective cohort study.Introduction to the Australian consensus guidelines for the management of neutropenic fever in adult cancer patients, 2010/2011. Australian Consensus Guidelines 2011 Steering Committee.Are the true impacts of adverse events considered in economic models of antineoplastic drugs? A systematic review.Cost-Effectiveness of Radiation and Chemotherapy for High-Risk Low-Grade Glioma.Risk of chemotherapy-induced neutropenic complications when treating patients with non-Hodgkin lymphoma.Optimizing Symptoms and Management of Febrile Neutropenia among Cancer Patients: Current Status and Future Directions.Adverse event-related costs for systemic metastatic breast cancer treatment among female Medicaid beneficiaries.Disease burden of systemic light-chain amyloidosis: a systematic literature review.Cost-Effectiveness Analysis of Second-Line Chemotherapy Agents for Advanced Gastric Cancer.Mechanism-based approach to the economic evaluation of pharmaceuticals: pharmacokinetic/pharmacodynamic/pharmacoeconomic analysis of rituximab for follicular lymphoma.Health resource consumption and costs attributable to chemotherapy-induced toxicity in German routine hospital care in lymphoproliferative disorder and NSCLC patients.Health-related quality of life anticipated with different management strategies for febrile neutropenia in adult cancer patients.Management of febrile neutropenia--a German prospective hospital cost analysis in lymphoproliferative disorders, non-small cell lung cancer, and primary breast cancer.The disease and economic burden of neutropenic fever in adult patients in Australian cancer treatment centres 2008: analysis of the Victorian Admitted Episodes Dataset.Safety Profile and Costs of Related Adverse Events of Trastuzumab Emtansine for the Treatment of HER2-Positive Locally Advanced or Metastatic Breast Cancer Compared to Capecitabine Plus Lapatinib from the Perspective of the Canadian Health-Care SystHospitalizations, outcomes, and management costs of febrile neutropenia in patients from a managed care population.Defining a therapeutic window for kinase inhibitors in leukemia to avoid neutropenia.Blood component use and associated costs after standard dose chemotherapy--a prospective analysis of routine hospital care in lymphoproliferative disorders and NSCLC in Germany.Economic evaluation for the US of nab-paclitaxel plus gemcitabine versus FOLFIRINOX versus gemcitabine in the treatment of metastatic pancreas cancer.The economic burden of common adverse events associated with metastatic colorectal cancer treatment in the United States.Comparison of filgrastim and pegfilgrastim to prevent neutropenia and maintain dose intensity of adjuvant chemotherapy in patients with breast cancer.
P2860
Q26798400-AE8F6EAC-B006-4E84-B29F-0CDC61CEFA96Q31142213-78C6397D-71E1-4423-8A04-789FB0329E09Q33387073-C102720F-079D-43E5-A82B-D49A5E942D40Q33391777-F62B9CE7-8D35-47F4-A232-F4A6EFA2B313Q33403054-E9379992-4B1D-4979-903E-1AC94C78A42FQ33431967-F9B7ED52-D5DA-4E8E-9D0C-F5C4F4E3105CQ33571191-DDB99A6A-0A78-4B1A-83C4-AC8FB6346439Q34627284-95EFE587-7E54-4C85-8950-E9F66FFDAD2FQ34677539-04029A4F-63B7-4827-8722-8D41DCFBE17AQ35006851-6EA08628-53AC-4822-B278-6A89ACFF2F04Q35053793-8EDF789B-ADF3-4A26-B092-94827810C575Q35730160-25ED6432-48DB-4139-868C-EBBD2182D73CQ36095199-CC3A8D5B-1FEA-4E64-A3B5-1A0A888EBB9FQ36516573-CAD1DCE3-08E2-44E2-8547-0A13A96FADE7Q36853019-0D15346D-88E3-4835-BE11-515F0B7B8CFBQ37387000-4CB4B0B4-60DA-4E5C-AB39-51299BC91CDBQ37554901-CDBFCB93-DF9F-4643-B186-089BF8CB7C45Q37703409-5C90B054-9941-4AF5-9960-B3F4EE34898CQ37832773-317A0142-989B-471C-B9C7-FE952F9CA805Q38152967-CF294961-5442-48CE-AD46-A870C4D3C1CEQ38699783-4BD972F6-3DDF-4317-8A50-0F636DCCD084Q38711166-E0FCC5A1-0CC6-43EB-AD3C-12931347BD01Q38749061-D51AEBB5-5D42-4256-BFCE-1F4897A9A142Q38840175-8E401D1B-70BD-4192-AA88-B8AA25257099Q38917828-77D6D599-7393-4DD3-A37C-7EE40C591482Q39015252-4944C1A3-3678-4DA6-B7A6-966DC68BF53CQ39639283-BAC0A017-7C58-42F8-8973-C9C93F211BEEQ39779938-5871D58B-6888-4DDD-AD06-6415FD152226Q40295657-4B396DD1-98F8-4B8F-8E76-665C3A67500DQ40324761-6E2592E6-D5CB-4C38-8683-BB30E93EC545Q40335959-CE5237C0-5C43-416D-AB8A-825726B2033AQ40784135-4C68941C-4C49-499A-ADF9-D199EE89123AQ41139035-C59242D4-9B3C-4CB9-9421-B9181FFA6A17Q41708770-CE40E587-4940-49F5-A360-D8E5473A04DFQ50537016-110C7988-54E3-42B6-A0BA-02E9BD1BEB91Q51284885-77E685E6-B219-4540-97B9-656BEC787AB0Q51459332-7544086C-A90A-483B-AE50-6E5C0A5CC83AQ53657728-3E93F799-079D-4CFD-BA6A-8F9C320772F2
P2860
Economic burden of haematological adverse effects in cancer patients: a systematic review.
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Economic burden of haematologi ...... patients: a systematic review.
@ast
Economic burden of haematologi ...... patients: a systematic review.
@en
type
label
Economic burden of haematologi ...... patients: a systematic review.
@ast
Economic burden of haematologi ...... patients: a systematic review.
@en
prefLabel
Economic burden of haematologi ...... patients: a systematic review.
@ast
Economic burden of haematologi ...... patients: a systematic review.
@en
P2093
P2860
P1476
Economic burden of haematologi ...... patients: a systematic review.
@en
P2093
P2860
P304
P356
10.2165/00044011-200727060-00002
P577
2007-01-01T00:00:00Z